This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
LOGC Aperçu des actions
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
LogicBio Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.07 |
| Plus haut sur 52 semaines | US$3.63 |
| Plus bas sur 52 semaines | US$0.26 |
| Bêta | 4.62 |
| 1Variation sur 1 mois | 0.98% |
| Variation sur 3 mois | 417.63% |
| Variation sur 1 an | -40.35% |
| 3Variation sur 3 ans | -76.79% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -82.00% |
Nouvelles et mises à jour récentes
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Rendement pour les actionnaires
| LOGC | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 0.5% | -4.0% | 0.6% |
| 1Y | -40.3% | 18.1% | 32.1% |
Rendement vs Industrie: LOGC underperformed the US Biotechs industry which returned -15.1% over the past year.
Rendement vs marché: LOGC underperformed the US Market which returned -21.9% over the past year.
Volatilité des prix
| LOGC volatility | |
|---|---|
| LOGC Average Weekly Movement | 179.9% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: LOGC's share price has been volatile over the past 3 months.
Volatilité au fil du temps: LOGC's weekly volatility has increased from 92% to 180% over the past year.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2014 | 62 | Fred Chereau | www.logicbio.com |
LogicBio Therapeutics, Inc. Résumé des fondamentaux
| LOGC statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$68.23m |
| Bénéfices(TTM) | -US$26.54m |
| Recettes(TTM) | US$10.76m |
6.3x
Ratio P/S-2.6x
Ratio P/ELe site LOGC est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| LOGC compte de résultat (TTM) | |
|---|---|
| Recettes | US$10.76m |
| Coût des recettes | US$30.68m |
| Marge brute | -US$19.92m |
| Autres dépenses | US$6.62m |
| Les revenus | -US$26.54m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -0.81 |
| Marge brute | -185.15% |
| Marge bénéficiaire nette | -246.71% |
| Ratio dettes/capitaux propres | 37.7% |
Quelles ont été les performances à long terme de LOGC?
Voir les performances historiques et les comparaisons